BioNTech reports that its Singapore subsidiary, BioNTech Pharmaceuticals Asia Pacific, has signed an agreement with Novartis Singapore Pharmaceutical Manufacturing to obtain one of its GMP-certified production facilities. This acquisition is a component of BioNTech’s expansion strategy for its global presence in Asia. Economic Development Council of Singapore (EDB), the facility will serve as BioNTech’s regional headquarters and become its first mRNA production facility in Singapore.
“We are excited to take another step towards expanding our global production of networked paints in Singapore, supporting the production of vaccines and mRNA-based treatments for the Asia-Pacific region. The acquisition provides us with the opportunity to boost the status quo of an mRNA production facility and thereby more rapidly develop the capacity for prospective clinical studies and the source of publicity for our vaccines and mRNA therapies for the region,” said Sierk Poetting. , PhD, COO of BioNTech. In the coming months, we will be working heavily with all parties on the site’s elegant transition as we continue to prepare for launch. “
“We are very pleased that BioNTech has selected Singapore as the location for its new regional headquarters and the first mRNA production facility in the Asia-Pacific region. The company’s investment demonstrates confidence in the strong skills base and deep production functions of our biopharmaceutical ecosystem. BioNTech’s presence will decorate Singapore’s mRNA functions and allow us to be prepared for a long-term pandemic in the region,” said Goh Wan Yee, senior vice president and chief healthcare officer, EDB.
BioNTech’s mRNA production facility in Singapore will create regional production functions in BioNTech’s pipeline of vaccines and mRNA-based remedies in the Asia-Pacific region at clinical and advertising scale, with the prospect of expanding production to other drug categories, such as mobile device remedies, a company spokesperson said. First, the facility will be supplied to manufacture a variety of mRNA-based products, as well as vaccines and legal remedies for infectious diseases. This would likely come with the company’s COVID-19 vaccine, as well as oncology product applicants if they evolved and were effectively approved or if they are legal through regulatory authorities.
The site will be a fully incorporated mRNA production facility offering mRNA production applications across the active ingredient and pharmaceutical, with an expected annual production capacity of up to several hundred million doses of mRNA-based vaccines after full deployment. The company expects more than one hundred jobs will be created in Singapore by 2024 in order to add operations, engineering, quality, finance, human resources and supply chain management. The plant will be part of BioNTech’s subsidiary, BioNTech Pharmaceuticals Asia Pacific, and will be fully incorporated into the global production network.
BioNTech is headquartered in Mainz, Germany. In addition to Singapore, the company’s other existing locations include Berlin, Halle, Idar-Oberstein, Marburg, Martinsried and Neuried, Germany; Cambridge, MA and Gaithersburg, MD; Istanbul, Turkey; Reading, United Kingdom; Shanghai, China; and Vienna, Austria.